Omeros announces positive data from OMS721 phase 2 trial
Omeros announced positive results in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy from the their Phase 2 clinical trial of OMS721 in TMAs, with clinically meaningful improvement in measures of red blood cell destruction. October 20, 2016